Log In
Wednesday 26th October 2016

MRSA vaccine breakthrough

31st October 2006

02082006_MRSA1.jpgScientists are moving closer to developing a vaccine to protect against the so-called hospital superbug MRSA.

Methicillin-resistant Staphylococcus aureus is an antibiotic resistant strain of the common bacteria Staphylococcus. It attacks people when their immune system is compromised by illness, and although it can be found in the community, it often colonises in hospitals.

Now researchers have found a vaccine that has protected mice from four strains of the potentially deadly bug, providing up to 100% immunity.

The team from the US, writing in the Proceedings of the National Academy of Sciences, said more work was needed before they could develop a vaccine for humans.

The team used recent advances in genetics to find a possible vaccine, sifting through the genome of Staphylococcus aureus to find proteins on the microbe that might spark the body's immune system into action.

The eventual vaccine gave the mice anything between 60 and 100% protection.

The team said further tests would be needed to understand the mechanism of the vaccine and to discover if it would be as effective in humans.

British experts have warned that further research is needed, looking at all the cross-sections of MRSA, including strains found outside the US.

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: MRSA vaccine breakthrough
Author: Martine Hamilton
Article Id: 1005
Date Added: 31st Oct 2006


BBC News

Recent Related Articles

Oral vaccine against Zika to be produced

Students urged to get meningitis W vaccine

Early promise for Zika vaccine


Add to scrapbook
Show Comments
Add comment
Find all related articles


M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2016